Linda Yaccarino joins health tech platform eMed as CEO after leaving X

Linda Yaccarino has embarked on a new chapter in her career by becoming the CEO of eMed Population Health, an innovative health tech startup focused on developing a platform for patients utilizing GLP-1 medications. This move comes after her two-year tenure as CEO at X, where she made notable strides in revitalizing the company's advertising strategy despite challenges. While Yaccarino may not have a background in health technology, eMed recognized her exceptional skills in forging partnerships and driving growth. Her visibility in the tech space, especially following her time at X, further enhances her appeal as a leader in this new venture. eMed previously launched a platform that facilitated the use of at-home COVID-19 rapid antigen tests, providing users with guidance on administering tests effectively. Currently, eMed is pivoting its focus to GLP-1 medications, including popular drugs like Ozempic, which are intended for weight management and the treatment of type 2 diabetes. Yaccarino emphasized the need for bold leadership in the evolving healthcare marketplace, stating, "To be a leader in today’s healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but also to redefine an entire industry." She expressed confidence in eMed's potential to become a pioneering force in improving global healthcare outcomes through its innovative services and technologies.